Novartis $6 Billion Notes Offering

"Davis Polk advised Novartis AG and Novartis Capital Corporation on an SEC-registered $6 billion notes offering issued by Novartis Capital Corporation and guaranteed by Novartis AG. The offering comprised seven tranches maturing between 2028 and 2055 with fixed and floating rates."

Davis Polk advised Novartis AG and Novartis Capital Corporation in connection with an SEC-registered $6 billion notes offering. The offering, issued by Novartis Capital Corporation and guaranteed by Novartis AG, totaled $6.0 billion and comprised seven tranches: $800 million of floating-rate notes due 2028; $700 million of 3.900% notes due 2028; $1.75 billion of 4.100% notes due 2030; $925 million of 4.300% notes due 2032; $925 million of 4.600% notes due 2035; $350 million of 5.200% notes due 2045; and $550 million of 5.300% notes due 2055. Davis Polk represented Novartis AG and Novartis Capital Corporation with a team composed by: partner Yasin Keshvargar and associate Nicole Groysman (corporate); partner Kara L. Mungovan and associate Hunter P. Shaw (tax); and counsel Sarah E. Kim and associates Caleb Beavers and Gianmarco Dedós Capote (’40 Act advice). All members of the Davis Polk team are based in the New York office.

Novartis $6 Billion Notes Offering

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads